Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Jean-Jacques Kiladjian1, Pierre Zachee2, Masayuki Hino3, Fabrizio Pane4, Tamas Masszi5, Claire N Harrison6, Ruben Mesa7, Carole B Miller8, Francesco Passamonti9, Simon Durrant10, Martin Griesshammer11, Keita Kirito12, Carlos Besses13, Beatriz Moiraghi14, Elisa Rumi15, Vittorio Rosti16, Igor Wolfgang Blau17, Nathalie Francillard18, Tuochuan Dong19, Monika Wroclawska20
1Hôpital Saint-Louis, Assitance Publique - Hôpitaux de Paris, Université de Paris, Inserm, Paris, France
2Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
3Department of Clinical Hematology, Osaka City University Graduate School of Medicine, Osaka, Japan
4University of Naples Federico II, Naples, Italy
53rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
6Guy’s and St Thomas’ NHS Foundation Trust, London, UK
7UT Health San Antonio Cancer Center, San Antonio, TX, USA
8Saint Agnes Cancer Institute, Baltimore, MD, USA
9Ospedale di Circolo e Fondazione Macchi, Varese, Italy
10Royal Brisbane and Women’s Hospital, Brisbane, Australia
11Johannes Wesling Clinic, University of Bochum, Minden, Germany
12Department of Hematology and Oncology, University of Yamanashi, Japan
13Haematology Department, Hospital del Mar-IMIM, Universidad Autónoma de Barcelona, Barcelona, Spain
14Hospital Jose Maria Ramos Mejia, Buenos Aires, Argentina
15Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
16Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
17Medical Department, Division of Hematology, Oncology, and Tumor Immunology, Charité Universitätsmedizin Berlin, Germany
18Novartis Pharma SAS, Rueil-Malmaison, France
19Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
20Novartis Pharma AG, Basel, Switzerland
Thông tin
Thông tin xuất bản
The Lancet Haematology
Tập 7
e226-e237
Thông tin tác giả